Earnings Ahead

INVA - Innoviva, Inc.

12.63 -0.01 -0.08

  1. Home
  2. Healthcare
  3. INVA
Innoviva, Inc.

Innoviva, Inc.

About

Profile

Headquarters

South San Francisco, California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

INVA



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Innoviva GAAP EPS of $0.02, revenue of $80.99M beats by $13.07M
  • Armata Pharmaceuticals gets $25M in financing and new executive chief
  • Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event
  • Innoviva, Entasis' bacterial pneumonia drug Xacduro wins FDA approval
  • Innoviva GAAP EPS of $0.51, revenue of $76.37M
  • Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts
  • Innoviva chairman Bickerstaff to step down after annual meeting
  • Innoviva rises 6% on FDA panel backing for bacterial pneumonia drug
  • InnovivaEPS of -$0.98, revenue of $65.8M beats by $6.95M
  • Zai Lab's bacterial infection drug gets priority review in China
  • Innoviva's bacterial infection drug gets FDA priority review
  • Innoviva GAAP EPS of $2.80, revenue of $67.26M
  • Innoviva GAAP EPS of $0.05, revenue of $108.22M
  • Goldman Sachs starts Innoviva with neutral rating, says royalty portfolio fairly valued
  • Royalty Pharma to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B
  • Innoviva to acquire La Jolla Pharma for $149M including debt
  • Innoviva to acquire Entasis Therapeutics for $2.20/share
  • La Jolla Pharmaceutical GAAP EPS of $0.00 misses by $0.01, revenue of $10.43M misses by $2.67M
  • Innoviva GAAP EPS of $0.20, revenue of $90.06M beats by $3.66M
  • La Jolla Pharmaceutical GAAP EPS of $0.11 beats by $0.07, revenue of $12.2M misses by $1.83M

Earnings History

Date EPS / Forecast Revenue / Forecast
February 9, 2022 0.14 / 0.41 107.68M / - Beat!
October 27, 2021 0.9 / 0.43 97.86M / - Beat!
July 28, 2021 0.9 / 0.29 100.81M / - Beat!
April 28, 2021 0.84 / -0.01 85.52M / - Beat!
February 3, 2021 0.48 / 0.4 90.48M / 75.3M Beat!
October 28, 2020 0.26 / 0.42 88.69M / 71.1M Beat!
July 29, 2020 0.69 / 0.32 68.95M / 68.3M Beat!
April 29, 2020 0.59 / 0.36 78.68M / 60.8M Beat!
February 5, 2020 0.42 / 0.5 75.97M / 71.8M Beat!
October 30, 2019 0.36 / 0.37 65.76M / 61.7M Beat!
July 24, 2019 0.34 / 0.43 64.11M / 68.9M
May 1, 2019 0.31 / 0.36 55.18M / 54.5M Beat!
February 7, 2018 - / 0.42 - / 67.41M
October 25, 2017 0.22 / 0.31 48.64M / 57.19M
July 26, 2017 0.30 / 0.31 58.56M / 50.53M Beat!
April 27, 2017 0.18 / 0.29 40.49M / - Beat!
February 9, 2017 0.18 / 0.27 43.61M / 46.41M
October 27, 2016 0.13 / 0.23 33.31M / 38.05M
Date Price Open High Low Vol Change ER
Mar 1 18.68 19.23
19.38
18.45
1.54M -2.76%
Feb 28 19.21 19.07
19.43
18.96
1.01M -0.88%
Feb 25 19.38 19.30
19.68
19.09
640.36K 0.57%
Feb 24 19.27 18.89
19.45
18.74
697.45K 0.52%
Feb 23 19.17 19.76
19.93
19.09
791.63K -0.1%
 
Feb 22 19.19 19.78
20.04
19.18
1.02M -4%
Feb 18 19.99 19.93
20.33
19.51
1.60M 0.25%
Feb 17 19.94 20.25
20.42
19.67
817.80K -1.53%
Feb 16 20.25 19.75
20.48
19.75
1.02M 2.84%
Feb 15 19.69 19.82
20.10
19.58
5.35M -0.1%
Feb 14 19.71 19.36
20.15
19.00
1.66M 2.39%
Feb 11 19.25 17.81
19.28
17.81
3.00M 6.94%
Feb 10 18.00 17.62
18.45
17.30
4.48M 13.71%
Feb 9 15.83 15.95
16.08
15.72
963.03K 0%
Feb 8 15.83 15.59
15.85
15.41
1.30M 1.15%
Feb 7 15.65 15.85
15.85
15.50
370.77K 0.06%
Feb 4 15.64 15.40
15.97
15.08
2.07M 1.56%
Feb 3 15.40 16.00
16.15
15.37
483.78K -5.11%
Feb 2 16.23 15.90
16.29
15.76
739.20K 2.72%